This study includes Part A and Part B. Part A is a dose-finding study for subjects with chronic liver disease-related thrombocytopenia scheduled for elective surgery. Part B is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study designed to evaluate the efficacy and safety of Herombopag compared to placebo in patients with chronic liver disease-related thrombocytopenia undergoing elective invasive surgery.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Part A: CL/F
Timeframe: 0 minute to 5 days
Part A: Vc/F
Timeframe: 0 minute to 5 days
Part A: ka
Timeframe: 0 minute to 5 days
Part A: Q/F
Timeframe: 0 minute to 5 days
Part A: AUC0-tau
Timeframe: 0 minute to 5 days
Part A: Cmax
Timeframe: 0 minute to 5 days
Part A: Kin
Timeframe: 0 minute to 35 days
Part A: Kout
Timeframe: 0 minute to 35 days
Part A: Kdeg
Timeframe: 0 minute to 35 days
Part A: Slope
Timeframe: 0 minute to 35 days
The proportion of subjects whose platelet count is ≥50×10^9/L within 24 hours before surgery and has increased by ≥20×10^9/L from baseline, and who have not received platelet transfusion or other treatments to raise platelet levels before surgery
Timeframe: 0 minute to 11 days